Does Aetna (CVS Health) Cover Alprostadil (Caverject/MUSE)?

What Is Alprostadil and Why Does Insurance Coverage Get Complicated?

Alprostadil is a synthetic prostaglandin E1 (PGE1) approved by the FDA for the treatment of erectile dysfunction [1]. It is sold under two delivery forms: Caverject (intracavernosal injection, 5 to 40 mcg per dose) and MUSE (medicated urethral system for erection, 125, 1 to 000 mcg intraurethral suppository) [2]. Both require a prescription, carry a list price near $600 per month, and sit outside the standard oral ED medication formulary track that most insurers prefer.

Coverage complexity arises because oral PDE5 inhibitors, sildenafil and tadalafil most commonly, are cheaper and easier to dispense. Aetna, like most commercial insurers, positions alprostadil as a second-line or third-line option after oral therapy has been tried and documented as inadequate. The 1996 Linet et al. randomized trial in the New England Journal of Medicine (N=296) established the efficacy benchmark: intracavernosal alprostadil produced successful intercourse in 94% of injection attempts versus 13.7% for placebo [3]. That evidence base is strong enough to support coverage, but the administrative gate is still real.

Because alprostadil is classified as a specialty drug on most Aetna formularies, the benefit may run through the medical benefit (for in-office Caverject administration) or the pharmacy benefit (for self-administered Caverject or MUSE), depending on the specific plan design. Confirming which benefit applies before submitting a PA request saves significant time [4].

Aetna Formulary Tier for Alprostadil (Caverject/MUSE)

Alprostadil sits on a non-preferred specialty tier, typically Tier 3 or Tier 4, across most Aetna commercial formularies. That tier placement carries cost implications even after prior authorization is approved.

On a standard Aetna commercial PPO, Tier 3 specialty drugs often require a 30 to 50% coinsurance rather than a flat copay. For a $600 monthly supply, that translates to $180, $300 out-of-pocket even with coverage in place. Some Aetna HMO plans have fixed specialty copays in the $60, $150 range per fill [5].

MUSE (alprostadil urethral suppository) and Caverject (alprostadil injection) are listed separately on the Aetna National Formulary, and their tier placement can differ by plan year. The formulary lookup tool at aetna.com should always be checked against the member's specific plan ID, since Aetna administers dozens of distinct formulary lists across employer group contracts [6].

Generic alprostadil injection compounding may be processed through a specialty pharmacy at reduced cost, but Aetna's clinical policy typically requires the branded product with documented medical necessity if the PA specifies it. Discussing the compounded versus branded question with your prescribing physician before submitting documentation matters here [7].

Prior Authorization Criteria for Alprostadil on Aetna

Prior authorization for alprostadil through Aetna is rated moderate-to-high difficulty. The PA is not automatic, and incomplete submissions are the leading cause of first-attempt denials.

Aetna's clinical policy for ED medications generally requires the following for alprostadil PA approval:

1. A confirmed diagnosis of erectile dysfunction documented in the medical record [8].
2. Documentation that at least one oral PDE5 inhibitor (sildenafil 50 to 100 mg or tadalafil 10 to 20 mg) was tried at an adequate dose for an adequate duration, typically 4 to 8 weeks, and either failed to produce a satisfactory erection or was contraindicated [9].
3. A statement of medical necessity from the prescribing physician, ideally a urologist or men's health specialist.
4. For Caverject specifically, documentation that the patient has received or will receive injection training (FDA labeling requires this) [2].

Contraindications to oral PDE5 inhibitors that Aetna recognizes include concurrent nitrate therapy, severe hepatic impairment, and certain cardiovascular instability diagnoses. Providing the specific contraindication code (e.g., concurrent isosorbide mononitrate) with the PA submission removes the step-therapy requirement entirely in most cases [10].

The American Urological Association guidelines on erectile dysfunction note that "intracavernosal injection therapy is an appropriate second-line therapy for men who fail or cannot tolerate oral PDE5 inhibitor therapy." [11] Using that exact guideline language in the PA letter of medical necessity has practical value when the reviewer is a non-specialist.

PA submissions go through Aetna's clinical review team, which has up to 3 business days for urgent requests and 14 calendar days for standard reviews under ACA regulations. Tracking the submission date and following up at day 10 if no decision has been communicated is standard practice [12].

Step Therapy Requirements Before Alprostadil

Aetna requires step therapy before approving alprostadil on most commercial plans. Step therapy means the insurer mandates a trial of a less expensive drug first.

For alprostadil, the required step is oral PDE5 inhibitor therapy. Sildenafil (generic available at $15, $30/month) or tadalafil (generic available at under $30/month) must be tried first. Aetna does not typically require both; documented failure of one is sufficient [13]. The documentation standard matters: a physician note stating "patient reports sildenafil was ineffective" carries less weight than a note specifying "sildenafil 100 mg was used on three separate occasions with adequate sexual stimulation and failed to produce a sufficient erection for penetration."

Step therapy exceptions exist. Per 26 states with enacted step therapy protection laws (as of 2024), a prescriber can submit a step therapy exception request if [14]:

• The required first-step drug is contraindicated for this patient.
• The patient already tried and failed the first-step drug before enrolling in this plan.
• The required drug causes or is reasonably expected to cause an adverse reaction.
• The patient is stable on alprostadil prescribed by another provider.

If your state has step therapy exception protections, the PA request should explicitly invoke them with supporting documentation. The National Conference of State Legislatures tracks which states have enacted these laws [14].

A practical submission framework: attach (1) the diagnosis note with ICD-10 code N52.9 or specific subtype, (2) the pharmacy dispensing record or physician note documenting the PDE5 inhibitor trial, (3) the letter of medical necessity citing AUA guideline support, and (4) any step therapy exception documentation if applicable. Submitting all four components in the first request reduces back-and-forth by an estimated one to two weeks.

How to Appeal an Aetna Denial of Alprostadil

Aetna denials for alprostadil coverage are appealable through a two-stage process. First-level internal appeals must be filed within 180 days of the denial notice on most Aetna commercial plans [15].

The denial letter will cite a specific clinical policy number and the exact reason for denial. Common denial reasons include:

• "Step therapy criteria not met" (the PDE5 inhibitor trial documentation was absent or insufficient).
• "Medical necessity not established" (the prescriber letter was too vague).
• "Drug not covered for this indication" (rare for alprostadil, but possible on some stripped-down employer plans) [16].

Each denial reason requires a targeted response. For a step therapy denial, attach the pharmacy records or physician notes directly. For a medical necessity denial, submit a peer-reviewed reference, the Linet et al. NEJM trial being the most cited [3], alongside the AUA guideline statement [11].

First-level internal appeal decisions must be issued within 30 days for non-urgent cases (15 days for urgent) under federal law. If the internal appeal is denied, the member has the right to an independent external review by an accredited Independent Review Organization (IRO) [15]. External reviewers are not employed by Aetna, and their decisions are binding on the insurer in most states.

Aetna's member appeals process is accessible through the member portal at aetna.com, by phone at the number on the back of the insurance card, or through a written request mailed to the address on the denial letter. Sending the appeal by certified mail creates a documented record of the submission date [17].

Data from the Kaiser Family Foundation's 2023 Employer Health Benefits Survey found that insurers overturn a meaningful percentage of denials at the internal appeal stage when additional clinical documentation is provided [18]. Filing the appeal with a complete clinical package, rather than a simple reconsideration request, consistently produces better outcomes.

What Alprostadil Treats: The Clinical Evidence Aetna Evaluates

Aetna's clinical policy reviewers evaluate alprostadil PA requests against the published evidence base for erectile dysfunction. Understanding what they see matters.

Erectile dysfunction affects an estimated 30 million men in the United States [19]. Alprostadil works by binding to prostaglandin receptors in penile smooth muscle, raising intracellular cyclic AMP, and causing smooth muscle relaxation and arterial dilation [20]. This mechanism is entirely distinct from PDE5 inhibition, which is why alprostadil works in men for whom sildenafil and tadalafil have failed.

The Linet et al. 1996 NEJM trial (N=296) remains the landmark study [3]. Intracavernosal alprostadil at doses from 2.5 to 20 mcg produced erections sufficient for intercourse in 94% of attempts, with a side-effect profile of transient penile pain in 50% of patients (mild in most cases) and priapism in 1% [3]. The MUSE formulation was separately evaluated: a multicenter trial published in the New England Journal of Medicine in 1997 (N=1,511) found that intraurethral alprostadil produced erections sufficient for intercourse in 64.9% of patients versus 18.6% for placebo [21].

Both studies are cited in AUA erectile dysfunction clinical guidelines [11], and both inform Aetna's clinical policy framework for this drug.

For men with diabetes-related ED, alprostadil retains efficacy where PDE5 inhibitors often fail. The prevalence of ED in men with type 2 diabetes reaches 50 to 75% [22], and glycemic dysregulation impairs the nitric oxide pathway that PDE5 inhibitors depend on. Alprostadil's cAMP-mediated mechanism bypasses that pathway entirely [20].

Cash-Pay and Savings Card Options If Aetna Denies Coverage

If Aetna denies coverage and the appeal process is exhausted, cash-pay and savings programs are options worth understanding.

The cash-pay average for alprostadil (Caverject or MUSE) runs approximately $600 per month at standard retail pharmacies [23]. GoodRx and similar discount programs may reduce the price of generic alprostadil injection to $150, $250 per month depending on pharmacy and dose, though prices vary significantly by region [23].

Pfizer's patient assistance program for Caverject (CaverjectCares) provides free or reduced-cost medication for patients who meet income eligibility criteria, generally at or below 400% of the federal poverty level. Applications are submitted directly through the manufacturer [24].

Manufacturer savings cards for Caverject are generally not stackable with commercial insurance under federal law. The Anti-Kickback Statute prohibits manufacturer coupons from reducing cost-sharing under federal health programs, and many commercial plans now include similar restrictions in their plan documents [25]. Using a savings card while enrolled in Aetna commercial coverage may violate plan terms. Verifying with your pharmacist before using any savings card is the right step.

Telehealth and compounding pharmacy routes exist as well. Compounded alprostadil injection (typically combined with papaverine and phentolamine as a "trimix" formulation) is not FDA-approved but is widely prescribed by urologists. Aetna does not cover compounded medications under the pharmacy benefit in most plan designs, but the out-of-pocket cost through a compounding pharmacy may be substantially lower than branded Caverject [26].

Aetna Medicare Advantage and Alprostadil

Medicare and Aetna Medicare Advantage plans handle alprostadil differently from commercial plans. Original Medicare Part D has historically excluded erectile dysfunction drugs from coverage, a statutory exclusion in the Medicare Modernization Act of 2003 [27]. Aetna Medicare Advantage plans generally follow this same exclusion unless the plan has specifically added an enhanced ED drug benefit.

One important exception exists: if alprostadil is administered in a physician's office as part of a diagnostic evaluation or treatment procedure, it may be billable under Medicare Part B as a covered service, separate from Part D drug coverage [28]. The physician's billing team handles this; the member generally does not need to file separately.

Men enrolled in Aetna Medicare Advantage plans should call the plan's member services line and ask specifically whether injectable alprostadil for erectile dysfunction is covered under either Part B (medical benefit) or Part D (pharmacy benefit) in their specific plan year, since plan designs change annually [29].

Working With Your Prescriber to Maximize Approval Odds

The prescribing physician's documentation is the single largest variable in whether a PA gets approved on the first submission.

A complete prior authorization package for alprostadil through Aetna should include: a chart note with the ICD-10 diagnosis code (N52.9 for unspecified male erectile dysfunction, or a more specific code such as N52.01 for erectile dysfunction due to arterial insufficiency), the name, dose, and duration of any previously tried PDE5 inhibitor, a letter of medical necessity that references the AUA erectile dysfunction guideline [11] and the Linet et al. NEJM trial [3], and, if step therapy exception applies, a statement of the specific exception criterion being invoked [14].

Prescribers who regularly manage men's health or urology patients often have PA templates on file. Asking the office whether they have a Caverject or MUSE PA template already submitted to Aetna reduces preparation time from days to hours.

The FDA prescribing information for Caverject states that the drug is "indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology." [2] Including that language in the letter of medical necessity aligns the submission directly with the approved label and gives the Aetna reviewer less grounds for a label-based denial.

Urologists who participate in Aetna's network also have peer-to-peer review rights: if a PA is denied, the prescribing physician can request a phone consultation with the Aetna medical director reviewing the case, present the clinical rationale directly, and ask for a real-time reversal. This peer-to-peer option is underused. The success rate for peer-to-peer reviews in urology is not published by Aetna, but clinical experience across the field suggests a meaningful percentage of denials are overturned when a urologist speaks directly with the reviewing physician [30].